Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.160
-0.055 (-1.71%)
At close: Sep 10, 2026, 4:00 PM EDT
3.160
0.00 (0.01%)
After-hours: Sep 10, 2026, 7:55 PM EDT
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 600 employees as of December 31, 2025. The number of employees decreased by 200 or -25.00% compared to the previous year.
Employees
600
Change (1Y)
-200
Growth (1Y)
-25.00%
Revenue / Employee
$91,427
Profits / Employee
-$864,807
Market Cap
1.69B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 600 | -200 | -25.00% |
| Dec 31, 2024 | 800 | 300 | 60.00% |
| Sep 30, 2024 | 500 | -50 | -9.09% |
| Jun 30, 2024 | 500 | -50 | -9.09% |
| Mar 31, 2024 | 500 | 0 | - |
| Dec 31, 2023 | 500 | 0 | - |
| Sep 30, 2023 | 550 | 50 | 10.00% |
| Jun 30, 2023 | 550 | 100 | 22.22% |
| Mar 31, 2023 | 500 | 50 | 11.11% |
| Dec 31, 2022 | 500 | 100 | 25.00% |
| Sep 30, 2022 | 500 | 170 | 51.52% |
| Jun 30, 2022 | 450 | 180 | 66.67% |
| Mar 31, 2022 | 450 | 232 | 106.42% |
| Dec 31, 2021 | 400 | 69 | 20.85% |
| Sep 30, 2021 | 330 | -1 | -0.30% |
| Jun 30, 2021 | 270 | - | - |
| Mar 31, 2021 | 218 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 524 |
| Maravai LifeSciences Holdings | 415 |
| Intellia Therapeutics | 377 |
| Syndax Pharmaceuticals | 298 |
| Kardigan | 241 |
| Lakefront Biotherapeutics NV | 196 |
| Inhibrx Biosciences | 110 |
| AnaptysBio | 104 |
RXRX News
- 24 days ago - Recursion Pharmaceuticals price target lowered to $5.30 from $5.50 at Morgan Stanley - TheFly
- 4 weeks ago - Recursion Pharmaceuticals Transcript: Bank of America SMID Cap Virtual Conference - Transcripts
- 5 weeks ago - Recursion Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Recursion Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Recursion Pharmaceuticals Earnings release: Q2 2026 - Filings
- 5 weeks ago - Recursion Pharmaceuticals Slides: Q2 2026 - Filings
- 5 weeks ago - Recursion Pharmaceuticals reports Q2 EPS (25c), consensus (23c) - TheFly
- 5 weeks ago - Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program - GlobeNewsWire